IDEAYA Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
IDEAYA Biosciences, Inc.
31.95
+2.01%
vs ±6.7% implied · ×0.30
shaded = implied · ▲▼ = realized
Linked news
IDEAYA Biosciences has 3 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceWe are conducting a Phase 1/2 clinical trial pursuant to a Clinical Study Collaboration and Supply Agreement (CSCSA) with Gilead to evaluate IDE397 in combination with Trodelvy (sacituzumab govitecan-hziy), Gilead's Trop-2 directed TOP1 ADC, in patients with MTAP-deletion urothelial cancer (UC), and non-small cell lung cancer (NSCLC).
SentenceWe are evaluating darovasertib in combination with crizotinib, Pfizer's oral c-MET inhibitor, in a potentially registration-enabling, Phase 2/3 trial (OptimUM-02) for human leukocyte antigen-A*02:01 negative (HLA*A2(-)), patients with first line (1L) mUM.
SentenceDosing of the first patient with IDE034 will trigger a $5.0 million milestone payment to Biocytogen, pursuant to our Option and License Agreement.
IDYA 10-Kaccession 0001193125-26-054533
SentenceIDE849 is a potential first-in-class, DLL3 TOP1 ADC being evaluated by our partner, Hengrui Pharma, in a multi-site, open label Phase 1 clinical trial in China in patients with small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC).
IDYA 10-Kaccession 0001193125-26-054533
SentenceIn August 2025, we entered into an exclusive license agreement with Les Laboratoires Servier (Servier), for the development and commercialization of darovasertib outside of the United States.
IDYA 10-Kaccession 0001193125-26-054533
Expected move
Inputs8Q avg ±4.2%·×1.72·rich
straddle ±10.8%
spot 31.96exp Nov 20ATM strike 32.5ATM straddle 4.08IV 66%